HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

50 For 50: All Talc-Containing Cosmetic Samples Found Asbestos-Free In Latest US FDA Tests

Executive Summary

No traces of asbestos were found in each of 50 talc-based cosmetic products a contract lab tested for FDA, an improvement over 17% of samples – nine of 52 products – testing positive for the carcinogen in the agency’s previous round.

You may also be interested in...



US FDA Wants Remote Regulatory Assessment Authority For Cosmetics – FY 2023 Budget Justification

After freezing its routine inspection activities at the height of the COVID-19 pandemic, the FDA adapted its oversight approach visibly in the drug and medical devices sectors, including with voluntary remote regulatory assessments. The agency now seeks authority to continue that work on a non-voluntary basis across all FDA-regulated programs.

US FDA Says White Paper Could Inform Rulemaking For Cosmetic Talc-Asbestos Testing

Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.

US FDA Support For Cosmetic Allergen Labeling Has Foundation In Consumers' ‘Right To Know’

Office of Cosmetics and Colors Linda Katz emphasizes FDA sees allergen labeling as a public health issue. While many allergic reactions are minor, “consumers who are extremely or exclusively sensitive to a particular ingredient should have a right to know.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS151879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel